Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

UV Clinical A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 2.2% 2.2%   Bankruptcy risk   15.1% 15.7% 14.6% 12.7% 9.1% 3.1% 8.9% 8.9%   Credit score (0-100)   14 13 14 17 26 56 28 28   Credit rating   BB BB BB BB BB BBB BB BB   Credit limit (kDKK)   -0.0 -0.0 -0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   3.7 -577 -411 33.5 151 2,235 0.0 0.0   EBITDA   -855 -1,426 -1,047 16.3 -1,280 -469 0.0 0.0   EBIT   -913 -1,484 -1,105 -41.7 -1,285 -469 0.0 0.0   Pre-tax profit (PTP)   -981.3 -1,571.3 -1,277.0 2,248.3 -1,297.8 -467.2 0.0 0.0   Net earnings   -798.7 -1,433.7 -1,149.2 2,248.3 -268.9 -417.2 0.0 0.0   Pre-tax profit without non-rec. items   -981 -1,571 -1,277 2,248 -1,298 -467 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -584 -975 -2,124 124 1,677 8,163 3,167 3,167   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,329 1,213 305 160 2,402 11,244 3,167 3,167   Net Debt   -923 -908 -15.9 -144 -686 -4,253 -3,167 -3,167     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   3.7 -577 -411 33.5 151 2,235 0.0 0.0   Gross profit growth   0.0% 0.0% 28.7% 0.0% 351.1% 1,380.9% -100.0% 0.0%   Employees   1 1 1 1 1 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,329 1,213 305 160 2,402 11,244 3,167 3,167   Balance sheet change%   90.1% -8.7% -74.8% -47.7% 1,403.3% 368.1% -71.8% 0.0%   Added value   -854.6 -1,426.2 -1,046.6 16.3 -1,226.8 -468.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -116 -116 -116 -116 587 4,962 -5,559 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -24,658.0% 257.4% 268.5% -124.6% -851.2% -21.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -69.9% -72.4% -47.8% 173.7% -100.3% -6.8% 0.0% 0.0%   ROI %   -79.8% -78.3% -50.1% 186.3% -142.7% -9.4% 0.0% 0.0%   ROE %   -103.5% -112.8% -151.4% 1,047.7% -29.9% -8.5% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -30.5% -44.6% -87.4% 77.5% 69.8% 72.6% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   108.1% 63.7% 1.5% -885.6% 53.6% 907.1% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   4.7 16.0 1.7 4.3 2.5 1.9 0.0 0.0   Current Ratio   4.7 16.0 1.7 4.3 2.5 1.9 0.0 0.0   Cash and cash equivalent   923.5 907.9 15.9 144.3 685.9 4,252.6 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   906.6 1,024.1 102.9 119.0 1,068.3 2,748.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -855 -1,426 -1,047 16 -1,227 -234 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -855 -1,426 -1,047 16 -1,280 -234 0 0   EBIT / employee   -913 -1,484 -1,105 -42 -1,285 -234 0 0   Net earnings / employee   -799 -1,434 -1,149 2,248 -269 -209 0 0